The availability of drugs for stable COPD treatment in China: a cross-sectional survey
Abstract This survey aimed to investigate the availability of drugs for stable chronic obstructive pulmonary disease (COPD) treatment in Chinese hospitals and to determine whether drug availability significantly varied among hospitals with different characteristics. A well-constructed questionnaire...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Primary Care Respiratory Medicine |
| Online Access: | https://doi.org/10.1038/s41533-025-00413-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586043688222720 |
|---|---|
| author | Dongru Du Xueru Hu Qiunan Zuo Dan Xu Tao Zhu Tao Fan Jiao Yang Weiguo Xu Hailong Wei Kangzhuo Baima Ying Zhang Yanhui Gu Lei Chen Fengming Luo Yongchun Shen Fuqiang Wen |
| author_facet | Dongru Du Xueru Hu Qiunan Zuo Dan Xu Tao Zhu Tao Fan Jiao Yang Weiguo Xu Hailong Wei Kangzhuo Baima Ying Zhang Yanhui Gu Lei Chen Fengming Luo Yongchun Shen Fuqiang Wen |
| author_sort | Dongru Du |
| collection | DOAJ |
| description | Abstract This survey aimed to investigate the availability of drugs for stable chronic obstructive pulmonary disease (COPD) treatment in Chinese hospitals and to determine whether drug availability significantly varied among hospitals with different characteristics. A well-constructed questionnaire was designed according to the Chinese Guidelines for the Diagnosis and Management of COPD (revised version 2021). Both inhaled drugs (monotherapy, double therapy and triple therapy) and oral drugs (expectorants, theophylline, antibiotics, and bacterial lysates) were included in this survey. Doctors from different hospitals completed the survey via WeChat. The availability of each category and kind of drug was analyzed based on final valid responses. Subgroup analyses were also conducted to reveal drug availability in hospitals with different characteristics. A total of 1018 hospitals with different characteristics were enrolled in this survey, with 53.73% of which establishing independent respiratory departments. Insufficient supply of COPD-related drugs was observed, with only short-acting β2 agonists (80.6%), expectorants (88.2%) and antibiotics (84.3%) reaching 80%. Results of subgroup analyses suggested that primary hospitals were associated with poorer availability of all kinds of drugs than secondary and tertiary hospitals (all p < 0.001). Most inhaled drugs did not reach an availability of 20% in primary hospitals, except for salbutamol (59.7%), tiotropium bromide (20.0%) and beclometasone/formoterol (23.1%). Results of this survey suggested that the availability of drugs for COPD treatment in China is still an ongoing challenge for healthcare institutions. Insufficient drug supply and imbalanced drug availability among different hospitals are major barriers that warrant further improvements. |
| format | Article |
| id | doaj-art-309d65a8a11a4804a36451afe9343af4 |
| institution | Kabale University |
| issn | 2055-1010 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Primary Care Respiratory Medicine |
| spelling | doaj-art-309d65a8a11a4804a36451afe9343af42025-01-26T12:15:42ZengNature Portfolionpj Primary Care Respiratory Medicine2055-10102025-01-013511810.1038/s41533-025-00413-1The availability of drugs for stable COPD treatment in China: a cross-sectional surveyDongru Du0Xueru Hu1Qiunan Zuo2Dan Xu3Tao Zhu4Tao Fan5Jiao Yang6Weiguo Xu7Hailong Wei8Kangzhuo Baima9Ying Zhang10Yanhui Gu11Lei Chen12Fengming Luo13Yongchun Shen14Fuqiang Wen15Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityRespiratory Ward, Department of Geriatrics, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of ChinaDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, Suining Central HospitalDepartment of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, Hunan University of Medicine General HospitalDepartment of Pulmonary and Critical Care Medicine, Mianyang Central HospitalDepartment of Pulmonary and Critical Care Medicine, The People’s Hospital of LeshanSchool of Medicine, Tibet UniversityDepartment of Pulmonary and Critical Care Medicine, Daping Hospital, Army Medical CenterDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical UniversityDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityDepartment of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan UniversityAbstract This survey aimed to investigate the availability of drugs for stable chronic obstructive pulmonary disease (COPD) treatment in Chinese hospitals and to determine whether drug availability significantly varied among hospitals with different characteristics. A well-constructed questionnaire was designed according to the Chinese Guidelines for the Diagnosis and Management of COPD (revised version 2021). Both inhaled drugs (monotherapy, double therapy and triple therapy) and oral drugs (expectorants, theophylline, antibiotics, and bacterial lysates) were included in this survey. Doctors from different hospitals completed the survey via WeChat. The availability of each category and kind of drug was analyzed based on final valid responses. Subgroup analyses were also conducted to reveal drug availability in hospitals with different characteristics. A total of 1018 hospitals with different characteristics were enrolled in this survey, with 53.73% of which establishing independent respiratory departments. Insufficient supply of COPD-related drugs was observed, with only short-acting β2 agonists (80.6%), expectorants (88.2%) and antibiotics (84.3%) reaching 80%. Results of subgroup analyses suggested that primary hospitals were associated with poorer availability of all kinds of drugs than secondary and tertiary hospitals (all p < 0.001). Most inhaled drugs did not reach an availability of 20% in primary hospitals, except for salbutamol (59.7%), tiotropium bromide (20.0%) and beclometasone/formoterol (23.1%). Results of this survey suggested that the availability of drugs for COPD treatment in China is still an ongoing challenge for healthcare institutions. Insufficient drug supply and imbalanced drug availability among different hospitals are major barriers that warrant further improvements.https://doi.org/10.1038/s41533-025-00413-1 |
| spellingShingle | Dongru Du Xueru Hu Qiunan Zuo Dan Xu Tao Zhu Tao Fan Jiao Yang Weiguo Xu Hailong Wei Kangzhuo Baima Ying Zhang Yanhui Gu Lei Chen Fengming Luo Yongchun Shen Fuqiang Wen The availability of drugs for stable COPD treatment in China: a cross-sectional survey npj Primary Care Respiratory Medicine |
| title | The availability of drugs for stable COPD treatment in China: a cross-sectional survey |
| title_full | The availability of drugs for stable COPD treatment in China: a cross-sectional survey |
| title_fullStr | The availability of drugs for stable COPD treatment in China: a cross-sectional survey |
| title_full_unstemmed | The availability of drugs for stable COPD treatment in China: a cross-sectional survey |
| title_short | The availability of drugs for stable COPD treatment in China: a cross-sectional survey |
| title_sort | availability of drugs for stable copd treatment in china a cross sectional survey |
| url | https://doi.org/10.1038/s41533-025-00413-1 |
| work_keys_str_mv | AT dongrudu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT xueruhu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT qiunanzuo theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT danxu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT taozhu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT taofan theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT jiaoyang theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT weiguoxu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT hailongwei theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT kangzhuobaima theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yingzhang theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yanhuigu theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT leichen theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT fengmingluo theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yongchunshen theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT fuqiangwen theavailabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT dongrudu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT xueruhu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT qiunanzuo availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT danxu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT taozhu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT taofan availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT jiaoyang availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT weiguoxu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT hailongwei availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT kangzhuobaima availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yingzhang availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yanhuigu availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT leichen availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT fengmingluo availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT yongchunshen availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey AT fuqiangwen availabilityofdrugsforstablecopdtreatmentinchinaacrosssectionalsurvey |